x Acta Scientific | International Open Library | Open Access Journals Publishing Group

Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Research Article Volume 4 Issue 12

Combination of Pycnogenol and Melatonin Reduce PC-3 and HT29 Cell Migration: Comparison to the Actions of Cisplatin

Ali Taghizadehghalehjoughi1*, Sidika Genc2, Yesim Yeni2, David R Wallace3, Ahmet Hacimuftuoglu2 and Zeynep Cakir4

1Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology, Ataturk University, Erzurum, Turkey
2Faculty of Medicine, Department of Medical Pharmacology, Ataturk University, Erzurum, Turkey
3Oklahoma State University Center for Health Sciences, School of Biomedical Sciences, Tulsa, Oklahoma, United States
4Faculty of Medicine, Department of Emergency Medicine, Ataturk University, Erzurum, Turkey

*Corresponding Author: Ali Taghizadehghalehjoughi, Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology, Ataturk University, Erzurum, Turkey.

Received: October 07, 2020; Published: November 30, 2020

Reprints View PDF Related Articles

×

Abstract

  Prostate and colorectal cancer are among the most common malignant tumors. The aim of the current study is to evaluate the effects of melatonin (MLT) and pycnogenol (PYG) combination on PC-3 and HT-29 cancer lines and to address the question of where or not MLT increases PYG antitumor effect in the PC-3 and HT-29 cancer lines. The combination of 100 μg/ml PYG + 40 μg/ml MLT reduced cell viability in both HT-29 and PC-3 cells (66 and 65%, respectively). Results from the TAC, TOS and LDH assays were correlated to our MTT results. In addition, the cellular migration test showed that the wound line was widened in the combination groups starting at 72 hours compared to the other groups. Cisplatin has routinely used as an anticancer agent, but because of side effects, usage is limitation. The combination of 40 μg/ml MLT with PYG increased the extent of antitumor effects compared to Cisplatin and reduced the cell viability effectively than Cisplatin. The combination of MLT + PYG shows promise to be a new anticancer agent for the treatment of HT-29 and PC-3 patients or adjuvant for the reduction of the side effects of chemotherapeutics.

Keywords: HT-29; Melatonin; PC-3; Pycnogenol

×

References

  1. Pandey KB and SI Rizvi. “Plant polyphenols as dietary antioxidants in human health and disease”. Oxidative Medicine and Cellular Longevity5 (2009): 270-278.
  2. Ajami M., et al. “Therapeutic role of sirtuins in neurodegenerative disease and their modulation by polyphenols”. Neuroscience and Biobehavioral Reviews 73 (2017): 39-47.
  3. Braicu C., et al. “Nutrigenomics in cancer: Revisiting the effects of natural compounds”. Seminars in Cancer Biology 46 (2017): 84-106.
  4. Tewari D., et al. “Ethnopharmacological Approaches for Dementia Therapy and Significance of Natural Products and Herbal Drugs”. Frontiers in Aging Neuroscience (2018): 10.
  5. Packer L., et al. “Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol”. Free Radical Biology and Medicine5-6 (1999): 704-724.
  6. Grimm T., et al. “Single and multiple dose pharmacokinetics of maritime pine bark extract (pycnogenol) after oral administration to healthy volunteers”. BMC Clinical Pharmacology 6 (2006): 4.
  7. Parveen K., et al. “Modulatory effects of Pycnogenol in a rat model of insulin-dependent diabetes mellitus: biochemical, histological, and immunohistochemical evidences”. Protoplasma1 (2013): 347-60.
  8. Gulati OP. “Pycnogenol (R) in Metabolic Syndrome and Related Disorders”. Phytotherapy Research 7 (2015): 949-968.
  9. Huynh HT and RW Teel. “Selective induction of apoptosis in human mammary cancer cells (MCF-7) by pycnogenol”. Anticancer Research 4 (2000): 2417-2420.
  10. Huang WW., et al. “Pycnogenol induces differentiation and apoptosis in human promyeloid leukemia HL-60 cells”. Leukemia Research 6 (2005): 685-692.
  11. Buz'Zard AR and BH Lau. “Pycnogenol reduces talc-induced neoplastic transformation in human ovarian cell cultures”. Phytotherapy Research 6 (2007): 579-86.
  12. Harati K., et al. “Proapoptotic effects of pycnogenol on HT1080 human fibrosarcoma cells”. International Journal of Oncology 4 (2015): 1629-1636.
  13. Stehle JH., et al. “A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases”. Journal of Pineal Research 1 (2011): 17-43.
  14. Tan DX., et al. “The changing biological roles of melatonin during evolution: from an antioxidant to signals of darkness, sexual selection and fitness”. Biological reviews of the Cambridge Philosophical Society 3 (2010): 607-623.
  15. Singh M and HR Jadhav. “Melatonin: functions and ligands”. Drug Discovery Today 9 (2014): 1410-2014418.
  16. Su SC., et al. “Cancer metastasis: Mechanisms of inhibition by melatonin”. Journal of Pineal Research 1 (2017).
  17. Tai SY., et al. “Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study”. Scientific Reports 6 (2016): 29606.
  18. Buldak RJ., et al. “Effects of ghrelin, leptin and melatonin on the levels of reactive oxygen species, antioxidant enzyme activity and viability of the HCT 116 human colorectal carcinoma cell line”. Molecular Medicine Reports 2 (2015): 2275-2282.
  19. Alonso-Gonzalez C., et al. “Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis”. Cancer Letters 1 (2016): 145-152.
  20. Zhou QY., et al. “Melatonin Inhibits the Migration of Human Lung Adenocarcinoma A549 Cell Lines Involving JNK/MAPK Pathway”. Plos One 7 (2014): e101132.
  21. Lu YX., et al. “Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway”. Cell Death and Disease (2016): 7.
  22. Ju HQ., et al. “Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation”. Journal of Pineal Research 1 (2016): 27-38.
  23. Kuipers EJ., et al. “Colorectal cancer”. Nature Reviews Disease Primers 1 (2015): 15065.
  24. Torre LA., et al. “Global cancer statistics, 2012”. CA: A Cancer Journal for Clinicians 2 (2015): 87-108.
  25. Zhang CZ., et al. “Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma”. Investigational New Drugs 1 (2015): 1-11.
  26. Bettuzzi S., et al. “Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study”. Cancer Research 2 (2006): 1234-1240.
  27. Shiu SYW. “Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment”. Journal of Pineal Research1 (2007): 1-9.
  28. Kumar NB., et al. “Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention”. Cancer Prevention Research10 (2015): 879-887.
  29. Rezzani R., et al. “Effects of Melatonin and Pycnogenol on Small Artery Structure and Function in Spontaneously Hypertensive Rats”. Hypertension 6 (2010): 1373-U161.
  30. Van der Zwan LP., et al. “Reduction of myeloperoxidase activity by melatonin and pycnogenol may contribute to their blood pressure lowering effect”. Hypertension3 (2010): e34-e35.
  31. Daneshmandi S., et al. “Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma”. Cancers4 (2019).
  32. Kamalak H., et al. “Cytotoxic and biological effects of bulk fill composites on rat cortical neuron cells”. Odontology4 (2018): 377-388.
  33. Taghizadehghalehjoughi A., et al. “Vincristine combination with Ca(+2) channel blocker increase antitumor effects”. Molecular Biology Reports 2 (2019): 2523-2528.
  34. Yilmaz A., et al. “Aloe Barbadensis Miller Increase Migration and Activity Properties of Fibroblast Cells: Induced DMSO Toxicity Model”. Acta Physiologica 227 (2019): 73-73.
  35. Stankovic MS., et al. “Teucrium Plant Species as Natural Sources of Novel Anticancer Compounds: Antiproliferative, Proapoptotic and Antioxidant Properties”. International Journal of Molecular Sciences 7 (2011): 4190-4205.
  36. Belcaro G., et al. “Pycnogenol (R) may alleviate adverse effects in oncologic treatment”. Panminerva Medica3 (2008): 227-234.
  37. Kim YJ., et al. “The anti-melanogenic effect of pycnogenol by its anti-oxidative actions”. Food and Chemical Toxicology 7 (2008): 2466-2471.
  38. Huang WW., et al. “Pycnogenol induces differentiation and apoptosis in human promyeloid leukemia HL-60 cells”. Leukemia Research 6 (2005): 685-692.
  39. Specian AF., et al. “LDH, proliferation curves and cell cycle analysis are the most suitable assays to identify and characterize new phytotherapeutic compounds”. Cytotechnology6 (2016): 2729-2744.
  40. Yang IH., et al. “Pycnogenol Induces Nuclear Translocation of Apoptosis-inducing Factor and Caspase-independent Apoptosis in MC-3 Human Mucoepidermoid Carcinoma Cell Line”. Journal of Cancer Prevention 4 (2014): 265-272.
×

Citation

Citation: Ali Taghizadehghalehjoughi., et al. “Combination of Pycnogenol and Melatonin Reduce PC-3 and HT29 Cell Migration: Comparison to the Actions of Cisplatin". Acta Scientific Pharmaceutical Sciences 4.12 (2020): 176-188.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"

Contact US





Creative Commons License Open Access by Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com

ff

Acta-Publications

ff

© 2021 Acta Scientific, All rights reserved.